ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2374

MRI of the Wrist in Early Rheumatoid Arthritis After 1-year Treat-to-target Strategy

Fan Xiao1, Jacky Ka Ko 1, Jiang Yue 1, James Griffith 1 and Lai-Shan Tam 1, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: remission and magnetic resonance imaging (MRI), Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: RA – Treatments Poster III: Safety and Outcomes

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Background:

There are two types of remission in rheumatoid arthritis. The first, and most commonly applied, is clinical remission. Imaging remission is another aspect to consider given that (a) the correlation between clinical and imaging at presentation is only modest, (b) imaging can show subclinical inflammation not evident clinically and (c) imaging evidence of inflammation can predict structural damage. In this study, we compared clinical and imaging remission in early rheumatoid arthritis (ERA) patients after one year of standard treatment.

Objective:

To semi-quantitatively and quantitatively measure the degree of inflammation (synovitis, tenosynovitis, bone marrow oedema) and structural change (erosions, joint space narrowing) on MRI in early RA patients following treat-to-target strategy treatment for one year and to compare this with change in clinical parameters.

Methods: Prospective cross-sectional study of 70 ERA patients underwent treat-to-target strategy treatment for one year. DAS28-ESR remission (DAS28-ESR score < 2.6), 2011 ACR/EULAR definition of remission, SDAI remission (SDAI ≤ 3.3) and Boolean remission was measured before and after treatment. High resolution MRI of the most symptomatic wrist was performed before and after treatment. MRI parameters including RAMRS subscores, synovial volume (synovitis and tenosynovitis), synovial perfusion (max enhancement, enhancement slope) were measured. 

Results: 55 (79%) out of 70 ERA patients completed baseline and one-year clinical and MRI assessments. Remission rates for DAS28-ESR, SDAI and Boolean were 60% (33), 44% (24) and 33% (18) respectively. Eight (24%) out of 33 patients with DAS28-ESR remission, showed progression in bone erosion.  Four (17%) of 24 patients with SDAI remission showed progression in bone erosion while 1 (5 %) of 18 patients with Boolean remission showed progression in bone erosion. Patients who achieved remission after treatment had a greater reduction in MRI-evident inflammation as well as bone erosion. At month 12, MRI-evident joint synovitis, tenosynovitis and bone marrow oedema was still frequently seen in ERA patients with clinical remission though patients who achieved Boolean remission had the lowest levels of joint synovitis, bone marrow oedema as well as bone erosion for all patients at one year.

Conclusion: MRI detected inflammation is common even in patients with clinical remission. Patients with Boolean remission had less residual inflammation than DAS28-ESR or SDAI remission patients. Treat to target protocols should ideally target Boolean remission.


Disclosure: F. Xiao, None; J. Ko, None; J. Yue, None; J. Griffith, None; L. Tam, None.

To cite this abstract in AMA style:

Xiao F, Ko J, Yue J, Griffith J, Tam L. MRI of the Wrist in Early Rheumatoid Arthritis After 1-year Treat-to-target Strategy [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/mri-of-the-wrist-in-early-rheumatoid-arthritis-after-1-year-treat-to-target-strategy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mri-of-the-wrist-in-early-rheumatoid-arthritis-after-1-year-treat-to-target-strategy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology